The Gov. Gavin Newloom recently signed a bill to fast-track a study of psychedelic drugs, which the veterans’ coalition says may have greater potential to treat chronic depression and anxiety.
More veterans are killed by homicide in America every day than the average daily deaths in Vietnam, Iraq and Afghanistan combined, according to data collected by the Department of Veterans Affairs.
A growing number of Service members are now turning to PsycheElics to treat mental health conditions caused by Wartime Trauma and traumatic brain injury.
The veterans of the organization ansofit who test the treatment solutions are big believers in the power of medicinal prices like Ibogaine, which the founder of the Navy Seal Marcus Calone Credits for saving his life.
This legislative cycle, vets sponsored a meeting written in 1103 to end the roadblock to allow the study of psychedelia in California.
“After 13 years as a Navy Seal and multiple deployments, I tried every conventional treatment available – none worked for me,” Capone said in a statement. “Ibogaine gave me my life back. With Ab 1103, California is taking the lead – empowering researchers to carry out rigorous studies with this program.”
AB 1103 inspired the California reform advisory panel, which is responsible for approving any studies involving the administration of Schedules 1 and 2 after receiving approval from the Food and Drug Administration.
Almost all PsycheDelics are classified as class 1 drugs, meaning they have no legal medical use and are considered a high risk of abuse. The advisory panel was established in 1968 and is intended to help ensure that studies involving psychedelic drugs are conducted safely and appropriately.
However, this additional requirement for approval, which is not available outside of California, can delay the start of studies.
Problems with the advisory panel became apparent last year when it could not meet for 11 months due to a dispute over a federal law requiring public meetings.
AB 1103 allows schedule 1 and 2 drugs to be approved without waiting for a full advisory panel meeting. Under the Bill, researchers who can demonstrate that their approved research already complies with California law will be eligible to have their proposal approved by a small group of Panel members during member days.
The bill goes into effect on Jan. 1, 2026, and is scheduled to serve until January 1, 2028
“This is an important time for science, for mental health, and for all veterans who have waited too long for better treatment options,” said Amber Capone, founder of the Executive of Vets, in a statement. “AB 1103 will accelerate the research needed to transform care, not just for veterans but all Californians affected by pain, addiction, and depression.”
Vets have sent more than 1,000 veterans to clinics in Mexico for Psychedelic treatment and are directing legislation across the country to renew the method used by the organization that has done the $50 million study
Bogaine, currently illegal in America, is among a number of Psychedelics that show promise in the treatment of PTSD depression and anxiety.
In a Stanford observational study on the effects of Ibogaine on 30 special forces veterans, participants saw an average reduction of 88% in PSD symptoms, 87% in depression symptoms and 81% in anxiety symptoms.
In addition, clinical studies of MDMA have shown strong results in the treatment of PSTD, while Oregon and Colon have legalized Psilocybin for use in depression, anxiety, grief and addiction.
